# The Efficacy and Safety of Caffeic Acid for Esophageal Cancer

> **NCT03070262** · PHASE3 · UNKNOWN · sponsor: **The First Affiliated Hospital of Henan University of Science and Technology** · enrollment: 300 (estimated)

## Conditions studied

- Esophagus Cancer

## Interventions

- **DRUG:** CA
- **DRUG:** placebo group

## Key facts

- **NCT ID:** NCT03070262
- **Lead sponsor:** The First Affiliated Hospital of Henan University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2020-12
- **Final completion:** 2021-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2020-11-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03070262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03070262, "The Efficacy and Safety of Caffeic Acid for Esophageal Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03070262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*